Across the whole pharma sector, there are four or five stocks big one out there which are going to gain market share. So, CDMO is one space within pharma which should do well as we go along. But pharma as a whole space per se has been doing okay and we continue to believe that incrementally also pharma should continue to do well in the coming year also.
One bitcoin bull cuts forecast by half as “cold breeze” blows
Standard Chartered has halved its bitcoin price forecasts for 2025 and 2026, citing weaker demand and a shift toward ETF-driven buying. Analyst Geoff Kendrick now